Last month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now Eli Lilly has struck a deal with the startup.
Ascidian chief scientific officer Robert Bell (L) overlooks research in the company's lab in Boston (courtesy Ascidian)
June 3, 2026 07:00 AM EDT
DealsCell/Gene Tx
Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
Ryan Cross
Eli Lilly signs $1.9B gene-editing deal with Ascidian Therapeutics
Lilly, Ascidian link up in RNA exon editing pact
Legend Biotech emerged as a rare market winner
A turning point for pancreatic cancer patients
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
Eli Lilly Deepens Innovation Push Through New Biopharma Collaborations - Eli Lilly (NYSE:LLY)
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Camurus announces expansion of Lilly collaboration
ASCO26: In vivo oncology approaches continue to show promise
The agreement gives Lilly exclusive rights to Ascidian's RNA exon-editing technology, which repairs faulty genes without altering…
Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney…
Eli Lilly said on Monday it would buy privately held blood cancer treatment developer Ajax Therapeutics for up to $2.3 billion…
Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a…
Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of…
The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.
